App Swedish Mutation (Appswe) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
App Swedish Mutation (Appswe) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The APP Swedish mutation (K670N/M671L) was the first identified pathogenic mutation in familial Alzheimer's disease, discovered in a Swedish family in 1992. This double mutation dramatically increases amyloid-beta production.
- Gene: APP (Amyloid Precursor Protein)
- Chromosome: 21q21.3
- Mutation: K670N/M671L (Lys670Asn, Met671Leu)
- cDNA Change: c.2149G>T, c.2152G>C
- Discovery: 1992, Swedish family (Mullan et al.)
- Inheritance: Autosomal dominant
The Swedish mutation is located at the β-secretase cleavage site:
- Normal: APP is cleaved at K670-M671 by BACE1 (β-secretase)
- Mutation: The K670N/M671L mutation creates an optimal BACE1 recognition sequence
- Result: 50-200% increase in total Aβ production
- Aβ40: Increased ~2-3 fold
- Aβ42: Increased ~5-10 fold (greater relative increase)
- Aβ42/Aβ40 ratio: Shifted toward more aggregation-prone Aβ42
This mutation provided critical insight into the amyloid cascade hypothesis and was instrumental in developing BACE1 inhibitors as AD therapeutics.
- Typical onset: 50-65 years (mean ~55 years)
- Range: 45-70 years
- Variability: Modified by other genetic and environmental factors
- Progressive memory loss: Typical AD presentation
- Cognitive decline: Rapid progression once symptoms begin
- Neuropsychiatric symptoms: Similar to sporadic AD
- Brain imaging: Typical AD pattern of hippocampal atrophy, cortical thinning
- Amyloid plaques: Extensive Aβ deposition throughout cortex
- Vascular amyloid: Cerebral amyloid angiopathy common
- Neurofibrillary tangles: Tau pathology consistent with AD
- Neuronal loss: Particularly in hippocampus and cortex
The Swedish mutation was key to developing BACE inhibitors:
- Proof of concept: Demonstrated that reducing Aβ production could prevent AD
- Drug development: Numerous BACE inhibitors entered clinical trials
- Challenges: Side effects from BACE1's normal functions (synaptic plasticity, myelination)
- Lecanemab, Donanemab: Target Aβ plaques; may be particularly effective
- Immunotherapy: Active and passive vaccines targeting Aβ
- Available: Clinical testing for APP mutations
- Indications: Early-onset AD family history, autosomal dominant pattern
- Counselling: Important given implications for family members
- APP Swedish mice: Widely used AD model (e.g., APPswe/PS1dE9, 5xFAD)
- Phenotype: Robust amyloid deposition, cognitive deficits
- Research value: Fundamental to understanding AD pathogenesis and testing therapies
App Swedish Mutation (Appswe) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of App Swedish Mutation (Appswe) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mullan M, et al. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nature Genetics.
- Citron M, et al. (1992). Beta-amyloid production: evidence for enhanced Aβ 40/42 ratio with Swedish mutation. Nature.
- Haass C, et al. (1995). The Swedish mutation causes early onset Alzheimer's disease by increasing beta-amyloid synthesis. Nature Medicine.